Alzheimer’s disease continues to provide the big drug development story for the new year thanks to Eli Lilly and Company’s announcement of a complete response letter for donanemab less than two weeks after the FDA approved Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab-irmb), but oncology is holding up its end with the recent approvals of supplemental indications for two targeted therapies, Seagen Inc.’s Tukysa (tucatinib) and BeiGene, Ltd.’s Brukinsa (zanubrutinib).
The Center for Biologics Evaluation and Research contributed a new claim for maternal use of Sanofi’s Adacel vaccine to...





